A Case of a 2-year-old Girl with Type I Gaucher Disease Presenting with Growth Retardation and Leg Pain

2세 여아에서 성장 부진과 다리 통증을 동반한 1형 고셔병 증례

  • Park, Yesul (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Hwang, Jae-Yeon (Department of Radiology, Pusan National University Children's Hospital) ;
  • Hwang, Eun Ha (Department of Pediatrics, Ulsan University Hospital) ;
  • Cheon, Chong Kun (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Lee, Beom Hee (Medical Genetics Center, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Yoo, Han-Wook (Medical Genetics Center, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Kim, Yoo-Mi (Department of Pediatrics, Pusan National University Children's Hospital)
  • 박예슬 (부산대학교 의과대학 부산대학교어린이병원 소아청소년과) ;
  • 황재연 (부산대학교 의과대학 부산대학교어린이병원 영상의학과) ;
  • 황은하 (울산대학교의과대학 소아청소년과) ;
  • 전종근 (부산대학교 의과대학 부산대학교어린이병원 소아청소년과) ;
  • 이범희 (서울아산병원 의학유전학과) ;
  • 유한욱 (서울아산병원 의학유전학과) ;
  • 김유미 (부산대학교 의과대학 부산대학교어린이병원 소아청소년과)
  • Published : 2017.08.30

Abstract

Gaucher disease (GD) is caused by the deficiency of glucocerebrosidase. In pediatric patients with GD, especially Type I GD, enzyme replacement therapy (ERT) can reduce the hepatosplenomegaly and improve the hematologic finding and growth velocity. Herein, we report a 2-year-old girl with Type I GD presented with hepatosplenomegaly, bone pain and growth retardation. A 2 year-old-girl was referred to our hospital due to severe hepatosplenomegaly and growth retardation. She suffered from both leg pain and chronic fatigue. Simple x-ray showed widened distal long bones like that of an 'Erlenmeyer flask' which is associated with GD. The laboratory test showed anemia and thrombocytopenia. The enzyme activity was markedly reduced and the direct sequencing of the GBA gene showed the compound heterozygous mutations, p.G46E and p.L444P. As the G46E have been considered as the protective gene against neuronopathic genotype, we could assess the Type I GD in this patient. After one year of ERT, the growth velocity became 11 cm per year. Bone pain and fatigue disappeared. The volume of liver and spleen was reduced from $683cm^3$ and $703cm^3$ to $590cm^3$ and $235cm^3$, respectively. Although GD is an extremely rare disease in Korea, growth retardation and bone pain in children are the important signs which lead to early detection of GD and a simple radiologic finding is helpful to assess the GD at outpatient clinic. We highlight that the early diagnosis and early ERT is important for good growth and outcome for pediatric patients with GD.

고셔병은 리소좀축적병으로 lysosomal hydrolase glucocerebrosidase 결여로 간비장비대, 골격계 증상, 빈혈, 혈소판 감소증의 증상을 나타내는 드문 상염색체 유전 질환이다. 본 증례에서는 2세 여아에서 간비장비대, 다리 통증, 성장부진이 관찰되어 시행한 단순 방사선 촬영 검사에 Erlenmeyer flask 변형을 확인하여 고셔병을 의심하였고 효소 분석 및 유전자 검사를 통해 확진하였다. 환아에서 한국인 비신경형 고셔병에서만 관찰되는 G46E 돌연변이를 확인하였고 1년 간의 효소 대체 요법을 통해 성장, 혈액학적 지표, 간비장비대 및 골증상의 호전을 확인하였기에 본 증례를 보고하는 바이다.

Keywords

References

  1. Thomas AS, Mehta A, Hughes DA. Gaucher disease: haematological presentations and Complications. Br J Haematol 2014;165(4):427-40. https://doi.org/10.1111/bjh.12804
  2. Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr AdolescMed 2006;160:603-8. https://doi.org/10.1001/archpedi.160.6.603
  3. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004;144:112-20. https://doi.org/10.1016/j.jpeds.2003.10.067
  4. Jeong SY, Park SJ, Kim HJ. Clinical and genetic characteristics of Korean patients with Gaucher disease. Blood Cells Mol Dis 2011;46:11-4. https://doi.org/10.1016/j.bcmd.2010.07.010
  5. Lee JY, Lee BH, Kim GH, Jung CW, Lee J, Choi JH, Yoo HW. Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups. Korean J Pediatr 2012;55:48-53. https://doi.org/10.3345/kjp.2012.55.2.48
  6. Kaplan P, Baris H, De Meirleir L, Di Rocco M, El-Beshlawy A, Huemer M, et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr 2013;172:447-58. https://doi.org/10.1007/s00431-012-1771-z
  7. Di Rocco M, Andria G, Deodato F, Giona F, Micalizzi C, Pession A. Early diagnosis of Gaucher disease in pediatric patients: proposal for a diagnostic algorithm. Pediatr Blood Cancer 2014;61:1905-9. https://doi.org/10.1002/pbc.25165
  8. Mistry PK, Cappellini MD, Lukina E, et al. A reappraisal of Gaucher disease-Diagnosis and disease management algorithms. Am J Hematol 2011;86:110-5. https://doi.org/10.1002/ajh.21888
  9. Grabowski GA, Andria G, Baldellou A, Campbell PE, Charrow J, Cohen IJ, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004;163(2):58-66. https://doi.org/10.1007/s00431-003-1362-0
  10. Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008;122:1182-90. https://doi.org/10.1542/peds.2007-2144
  11. Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 2015;385:2355-62. https://doi.org/10.1016/S0140-6736(14)61841-9